Alumis (ALMS) Competitors $4.02 +0.06 (+1.52%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$4.06 +0.04 (+1.00%) As of 10/3/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALMS vs. TWST, COGT, BHVN, HRMY, PAHC, VCEL, AVDL, GPCR, SDGR, and ABCLShould you be buying Alumis stock or one of its competitors? The main competitors of Alumis include Twist Bioscience (TWST), Cogent Biosciences (COGT), Biohaven (BHVN), Harmony Biosciences (HRMY), Phibro Animal Health (PAHC), Vericel (VCEL), Avadel Pharmaceuticals (AVDL), Structure Therapeutics (GPCR), Schrodinger (SDGR), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. Alumis vs. Its Competitors Twist Bioscience Cogent Biosciences Biohaven Harmony Biosciences Phibro Animal Health Vericel Avadel Pharmaceuticals Structure Therapeutics Schrodinger AbCellera Biologics Twist Bioscience (NASDAQ:TWST) and Alumis (NASDAQ:ALMS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Do analysts recommend TWST or ALMS? Twist Bioscience presently has a consensus price target of $48.90, suggesting a potential upside of 57.39%. Alumis has a consensus price target of $20.17, suggesting a potential upside of 401.66%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 2 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.55Alumis 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Which has more volatility & risk, TWST or ALMS? Twist Bioscience has a beta of 2.38, meaning that its share price is 138% more volatile than the S&P 500. Comparatively, Alumis has a beta of -1.47, meaning that its share price is 247% less volatile than the S&P 500. Which has higher earnings and valuation, TWST or ALMS? Twist Bioscience has higher revenue and earnings than Alumis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$312.97M5.99-$208.73M-$1.45-21.43AlumisN/AN/A-$294.23MN/AN/A Does the media refer more to TWST or ALMS? In the previous week, Twist Bioscience had 2 more articles in the media than Alumis. MarketBeat recorded 4 mentions for Twist Bioscience and 2 mentions for Alumis. Alumis' average media sentiment score of 1.66 beat Twist Bioscience's score of 0.22 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Alumis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is TWST or ALMS more profitable? Alumis has a net margin of 0.00% compared to Twist Bioscience's net margin of -23.51%. Twist Bioscience's return on equity of -29.03% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-23.51% -29.03% -21.77% Alumis N/A -119.15%-92.50% SummaryTwist Bioscience beats Alumis on 7 of the 12 factors compared between the two stocks. Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALMS vs. The Competition Export to ExcelMetricAlumisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$418.34M$3.36B$6.13B$10.58BDividend YieldN/A2.28%5.65%4.69%P/E RatioN/A22.2886.9626.71Price / SalesN/A458.33604.82131.77Price / CashN/A47.8637.9061.31Price / Book0.739.9312.556.55Net Income-$294.23M-$52.80M$3.31B$277.50M7 Day Performance-0.74%5.22%4.28%2.42%1 Month Performance-10.86%10.61%6.90%8.63%1 Year Performance-58.73%25.03%70.54%31.60% Alumis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALMSAlumis3.7169 of 5 stars$4.02+1.5%$20.17+401.7%-58.7%$418.34MN/A0.00N/ANews CoveragePositive NewsTWSTTwist Bioscience3.7033 of 5 stars$26.89+0.5%$49.40+83.7%-28.3%$1.62B$312.97M-18.55990Analyst ForecastCOGTCogent Biosciences2.686 of 5 stars$14.14+6.4%$20.00+41.5%+41.9%$1.61BN/A-7.9480BHVNBiohaven3.1809 of 5 stars$14.98+8.4%$48.85+226.0%-66.8%$1.59BN/A-1.96239Positive NewsHRMYHarmony Biosciences4.6587 of 5 stars$27.53+1.8%$45.50+65.3%-21.2%$1.58B$714.73M8.88200PAHCPhibro Animal Health4.5778 of 5 stars$38.84+2.1%$28.40-26.9%+79.8%$1.57B$1.30B32.922,475Positive NewsVCELVericel3.1551 of 5 stars$30.23+1.3%$60.40+99.8%-25.2%$1.53B$237.22M251.96300Positive NewsAVDLAvadel Pharmaceuticals3.128 of 5 stars$15.34+0.1%$20.86+35.9%+14.7%$1.49B$169.12M-511.4770GPCRStructure Therapeutics3.1311 of 5 stars$25.03+0.1%$68.67+174.4%-36.5%$1.44BN/A-23.83136SDGRSchrodinger3.3813 of 5 stars$19.29+1.4%$27.83+44.3%+17.6%$1.42B$207.54M-7.78790News CoverageAnalyst DowngradeABCLAbCellera Biologics3.2024 of 5 stars$4.75+2.0%$8.00+68.6%+136.0%$1.42B$28.83M-8.63500News CoverageGap Up Related Companies and Tools Related Companies TWST Alternatives COGT Alternatives BHVN Alternatives HRMY Alternatives PAHC Alternatives VCEL Alternatives AVDL Alternatives GPCR Alternatives SDGR Alternatives ABCL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALMS) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.